K
Kouji Joko
Researcher at University of Toyama
Publications - 104
Citations - 4238
Kouji Joko is an academic researcher from University of Toyama. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 20, co-authored 84 publications receiving 1181 citations. Previous affiliations of Kouji Joko include Ehime University.
Papers
More filters
Journal ArticleDOI
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Atsushi Hiraoka,Takashi Kumada,Masatoshi Kudo,Masashi Hirooka,Kunihiko Tsuji,Ei Itobayashi,Kazuya Kariyama,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Toshifumi Tada,Hidenori Toyoda,Kazuhiro Nouso,Kouji Joko,Hideki Kawasaki,Yoichi Hiasa,Kojiro Michitaka +16 more
TL;DR: ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making and prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score.
Journal ArticleDOI
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Atsushi Hiraoka,Takashi Kumada,Masanori Atsukawa,Masashi Hirooka,Kunihiko Tsuji,Toru Ishikawa,Koichi Takaguchi,Kazuya Kariyama,Ei Itobayashi,Kazuto Tajiri,Noritomo Shimada,Hiroshi Shibata,Hironori Ochi,Toshifumi Tada,Hidenori Toyoda,Kazuhiro Nouso,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Korenobu Hayama,Michitaka Imai,Kouji Joko,Yohei Koizumi,Yoichi Hiasa,Kojiro Michitaka,Masatoshi Kudo +25 more
TL;DR: Appropriate factors indicating newly developed lenvatinib treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients are assessed.
Journal ArticleDOI
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Atsushi Hiraoka,Takashi Kumada,Kunihiko Tsuji,Koichi Takaguchi,Ei Itobayashi,Kazuya Kariyama,Hironori Ochi,Kazuto Tajiri,Masashi Hirooka,Noritomo Shimada,Toru Ishikawa,Yoshihiko Tachi,Toshifumi Tada,Hidenori Toyoda,Kazuhiro Nouso,Kouji Joko,Yoichi Hiasa,Kojiro Michitaka,Masatoshi Kudo +18 more
TL;DR: The detailed stratification ability of mALBI grade for hepatic reserve function is suitable for the recent trend of HCC patients, whilemALBI-T may provide a more accurate predictive value than existing total staging scoring systems.
Journal ArticleDOI
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
Atsushi Hiraoka,Takashi Kumada,Kazuya Kariyama,Koichi Takaguchi,Masanori Atsukawa,Ei Itobayashi,Kunihiko Tsuji,Kazuto Tajiri,Masashi Hirooka,Noritomo Shimada,Hiroshi Shibata,Toru Ishikawa,Hironori Ochi,Toshifumi Tada,Hidenori Toyoda,Kazuhiro Nouso,Akemi Tsutsui,Norio Itokawa,Michitaka Imai,Kouji Joko,Yoichi Hiasa,Kojiro Michitaka +21 more
TL;DR: This work aimed to elucidate the therapeutic efficacy of lenvatinib (LEN), a newly developed first‐line tyrosine kinase inhibitor (TKI), obtained in real‐world practice.
Journal ArticleDOI
Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients.
Masahiko Koda,Yoshikazu Murawaki,Yasuaki Hirooka,Mikiya Kitamoto,Masafumi Ono,Hiroshi Sakaeda,Kouji Joko,Shuichi Sato,Katsuyoshi Tamaki,Takahiro Yamasaki,Hiroshi Shibata,Toshinari Shimoe,Tadakazu Matsuda,Nobuyuki Toshikuni,Shin Fujioka,Kenji Ohmoto,Shinichiro Nakamura,Kazuya Kariyama,Hiroshi Aikata,Yoshiyuki Kobayashi,Akemi Tsutsui +20 more
TL;DR: This work surveyed multiple centers to identify types and frequency of complications and mortality rate associated with radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC).